UGT1A1 and colorectal carcinoma: The aims of this phase I trial are the definition, on the basis of UGT1A1 genotype, of the maximally-tolerated dose of irinotecan in FOLFIRI plus bevacizumab as first-line therapy in metastatic CRC patients and to define whether bevacizumab alters irinotecan PK.